Cannabinoid formulations
The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.
1. A formulation comprising:
a cannabidiol (CBD) and a tetrahydrocannabinol (THC), wherein the formulation has a CBD:THC ratio from about 1:1 to about 1:5;
a primary terpene of myrcene at about 3-5%; and
a secondary terpene of linalool at about 1-5%.
2. The formulation of claim 1 , comprising branched-chain amino acids, L-glutamine, piperine, magnesium stearate, MCC, and silicon dioxide, wherein the CBD:THC ratio is about 1:2.
3. The formulation of claim 1 , wherein the formulation comprises less than about 25%, 20%, 15%, 10%, 5%, 4%, 3%, or 2% terpenes.
4. The formulation of claim 1 , wherein the formulation further comprises cannabigerol (CBG), cannabinol (CBN), cannabidvarin (CBDV), cannabidiolic acid (CBDA), tetrahydrocannabinolic acid (THCA), or tetrahydrocannabivarin (THCV).
5. The formulation of claim 1 , wherein the formulation further comprises black pepper, branched-chain amino acids (BCAA), cayenne, cedarwood, chamomile, coconut oil, geranium, ginger, ginger oil, glutamine, guava, juniper berry, lavender, lemon, lemon oil, lemongrass, lime, lime oil, orange, orange oil, mango, marjoram, menthol, mint, mint oil, peppermint, peppermint oil, piperine, geranium, rosemary, sandalwood, or tangerine.
6. The formulation of claim 1 , comprising 5% myrcene and 3% linalool, wherein the CBD: THC ratio is about 1:1.
7. The formulation of claim 1 , further comprising terpinolene.
8. The formulation of claim 7 , comprising 1-3% terpinolene.
9. The formulation of claim 1 , further comprising lavender, chamomile, and sandalwood.
10. The formulation of claim 9 , comprising 0 .04-0.1% lavender, 0.04-0.1% chamomile, and 0.04-0.1% sandalwood.